Delivery Order SPE2DB22D3501-SPE2DB25FVR41
Award Date
5/14/25
Potential Completion Date
5/15/25
Potential Value
$3.7K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $2,593.04, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 4,568,090,280 units of Vyvanse 70 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm fixed-price, non-set-aside award with a performance period ending on May 1, 2025. AmerisourceBergen Drug Corp...
This federal contract award, valued at $4,401.60, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Vyvanse 30 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of April 18, 2025. This contract is not set aside for any specific business type. AmerisourceBergen Drug Corp...
This federal contract award, valued at $5,216.10, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,966,088 units of Vyvanse 20 mg capsules, a medication used to treat ADHD. The contract is a delivery order, with a firm fixed price pricing type and an ultimate completion date of April 18, 2025. Amerisourcebergen Drug Corp is the prime contractor, and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,638.64 firm fixed-price delivery order is for the supply of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of November 4, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $4,127.86, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The award covers the delivery of 4,564,570,281 units of Vyvanse 30 mg capsules, a drug used for the treatment of attention-deficit/hyperactivity disorder (ADHD). The contract is a Firm Fixed Price Delivery Order with a period of performance through May 13, 2024. It is not designated as a...
This federal contract award, valued at $3,710.99, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 40 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $4,694.58, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order contract for the supply of Vyvanse 40 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 23, 2025. Amerisourcebergen Drug Corp...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,566,359,320 units of Vyvanse 50 mg capsules. The contract has a ceiling value of $4,006.50 and is a firm-fixed price delivery order, with a period of performance through November 7, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award, valued at $6,639.66, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4567748146 Vyvanse 40 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a completion date of March 28, 2025 and is a Firm Fixed Price Delivery Order. There is no set-aside designation indicated for this...
This federal contract award, valued at $12,170.72, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse capsules, a prescription medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). The contract has a completion date of May 15, 2024 and is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between...